Nanocarriers as an emerging platform for cancer therapy

Dan Peer*, Jeffrey M. Karp, Seungpyo Hong, Omid C. Farokhzad, Rimona Margalit, Robert Langer

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Nanotechnology has the potential to revolutionize cancer diagnosis and therapy. Advances in protein engineering and materials science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients. Several therapeutic nanocarriers have been approved for clinical use. However, to date, there are only a few clinically approved nanocarriers that incorporate molecules to selectively bind and target cancer cells. This review examines some of the approved formulations and discusses the challenges in translating basic research to the clinic. We detail the arsenal of nanocarriers and molecules available for selective tumour targeting, and emphasize the challenges in cancer treatment.

Original languageEnglish
Pages (from-to)751-760
Number of pages10
JournalNature Nanotechnology
Volume2
Issue number12
DOIs
StatePublished - Dec 2007

Funding

FundersFunder number
NIH/NCICA119349
NIH/NIBIBEB 003647
National Institutes of Health
National Institute of Biomedical Imaging and BioengineeringR01EB000244

    Fingerprint

    Dive into the research topics of 'Nanocarriers as an emerging platform for cancer therapy'. Together they form a unique fingerprint.

    Cite this